Use of antimicrobials and risk of type 1 diabetes in a population-based mother-child cohort

Diabetologia

Volumn 49, Issue 1, 2006, Pages 66-70

  Kilkkinen, A ^a   Virtanen, S M ^a,b,g   Klaukka, T ^c   Kenward, M G ^d   Salkinoja Salonen, M ^e   Gissler, M ^a   Kaila, M ^f   Reunanen, A ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF TAMPERE   (Finland)

^c SOCIAL INSURANCE INSTITUTION   (Finland)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITY OF HELSINKI   (Finland)

^f TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^g TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Antimicrobial agents; Child; Pregnancy; Registries; Type 1 diabetes mellitus

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN; MACROLIDE; PENICILLIN G; PENICILLIN V; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE; TRIMETHOPRIM;

ANTIMICROBIAL THERAPY; ARTICLE; CHILDHOOD DISEASE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; FINLAND; HUMAN; INFANT; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; POPULATION RISK; PREGNANCY; PRENATAL DRUG EXPOSURE; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; RISK ASSESSMENT;

ADULT; ANTI-INFECTIVE AGENTS; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; FINLAND; HUMANS; MOTHERS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS;

EID: 31444443437     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-0078-2     Document Type: Article

References (12)

1. Knip M, Veijola R, Virtanen S, Hyöty H, Vaarala O, Åkerblom H (2005) Environmental triggers and determinants of type 1 diabetes. Diabetes 54(Suppl 2):S125-S136
2. Gissler M, Teperi J, Hemminki E, Merilainen J (1995) Data quality after restructuring a national medical registry. Scand J Soc Med 23:75-80
3. Sullivan A, Edlund C, Nord CE (2001) Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 1:101-114
4. Kimura K, McCartney AL, McConnell MA, Tannock GW (1997) Analysis of fecal populations of bifidobacteria and lactobacilli and investigation of the immunological responses of their human hosts to the predominant strains. Appl Environ Microbiol 63:3394-3398
5. Hayem G, Petit PX, Levacher M, Gaudin C, Kahn MF, Pocidalo JJ (1994) Cytofluorometric analysis of chondrotoxicity of fluoroquinolone antimicrobial agents. Antimicrob Agents Chemother 38:243-247
6. Jun YT, Kim HJ, Song MJ et al (2003) In vitro effects of ciprofloxacin and roxithromycin on apoptosis of jurkat T lymphocytes. Antimicrob Agents Chemother 47:1161-1164
7. Myers MA, Mackay IR, Rowley MJ, Zimmet PZ (2001) Dietary microbial toxins and type 1 diabetes - a new meaning for seed and soil. Diabetologia 44:1199-1200
8. Hettiarachchi KD, Zimmet PZ, Myers MA (2004) Transplacental exposure to bafilomycin disrupts pancreatic islet organogenesis and accelerates diabetes onset in NOD mice. J Autoimmun 22:287-296
9. Foulds G, Shepard RM, Johnson RB (1990) The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 25(Suppl A):73-82
10. Rimmele T, Boselli E, Breilh D et al (2004) Diffusion of levofloxacin into bone and synovial tissues. J Antimicrob Chemother 53:533-535
11. Kim JC, Bae CS, Kim SH et al (2003) Transplacental pharmacokinetics of the new fluoroquinolone DW-116 in pregnant rats. Toxicol Lett 142:103-109
12. Witt A, Sommer EM, Cichna M et al (2003) Placental passage of clarithromycin surpasses other macrolide antibiotics. Am J Obstet Gynecol 188:816-819